ATE520414T1 - Protein c zur verwendung bei der aufrechterhaltung der hämostase - Google Patents

Protein c zur verwendung bei der aufrechterhaltung der hämostase

Info

Publication number
ATE520414T1
ATE520414T1 AT08771345T AT08771345T ATE520414T1 AT E520414 T1 ATE520414 T1 AT E520414T1 AT 08771345 T AT08771345 T AT 08771345T AT 08771345 T AT08771345 T AT 08771345T AT E520414 T1 ATE520414 T1 AT E520414T1
Authority
AT
Austria
Prior art keywords
protein
bleeding
maintaining hemostasis
subject
disorder
Prior art date
Application number
AT08771345T
Other languages
English (en)
Inventor
Owen Mccarty
Andras Gruber
John Griffin
Original Assignee
Univ Oregon Health & Science
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Scripps Research Inst filed Critical Univ Oregon Health & Science
Application granted granted Critical
Publication of ATE520414T1 publication Critical patent/ATE520414T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT08771345T 2007-06-18 2008-06-18 Protein c zur verwendung bei der aufrechterhaltung der hämostase ATE520414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94469307P 2007-06-18 2007-06-18
PCT/US2008/067321 WO2008157593A2 (en) 2007-06-18 2008-06-18 Protein c for use in maintaining hemostasis

Publications (1)

Publication Number Publication Date
ATE520414T1 true ATE520414T1 (de) 2011-09-15

Family

ID=39917120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08771345T ATE520414T1 (de) 2007-06-18 2008-06-18 Protein c zur verwendung bei der aufrechterhaltung der hämostase

Country Status (6)

Country Link
US (1) US20100184672A1 (de)
EP (1) EP2178556B1 (de)
AT (1) ATE520414T1 (de)
AU (1) AU2008265770A1 (de)
CA (1) CA2691095A1 (de)
WO (1) WO2008157593A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618899T3 (es) * 2010-02-26 2017-06-22 The Children's Hospital Of Philadelphia Zimógeno de proteína C y procedimientos de utilización del mismo para prevenir las metástasis del cáncer
EP3388068A1 (de) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
MX390699B (es) 2011-06-21 2025-03-21 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
US9642896B1 (en) 2011-11-14 2017-05-09 Yale University Compositions and methods for modulating coagulation
US20150366952A1 (en) * 2014-06-24 2015-12-24 Saint Louis University Methods for reducing fibrosis induced by peritoneal dialysis
JP2017535552A (ja) 2014-11-17 2017-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
JP7735288B2 (ja) 2020-02-18 2025-09-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
EP0651655A4 (de) * 1992-07-24 1996-05-29 Oklahoma Med Res Found Blockierung der protein c aktivierung reduziert den blutverlust in mikrogefässen bei chirurgischen eingriffen.
WO2001036462A2 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US7498305B2 (en) * 2003-07-08 2009-03-03 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
WO2006018204A1 (en) * 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant

Also Published As

Publication number Publication date
AU2008265770A1 (en) 2008-12-24
EP2178556A2 (de) 2010-04-28
CA2691095A1 (en) 2008-12-24
EP2178556B1 (de) 2011-08-17
WO2008157593A2 (en) 2008-12-24
WO2008157593A3 (en) 2009-03-19
US20100184672A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
ATE520414T1 (de) Protein c zur verwendung bei der aufrechterhaltung der hämostase
EP2547355A4 (de) Tfpi-hemmer und verwendungsverfahren dafür
MX2011013459A (es) Terapia de peptido para incrementar los niveles de plaquetas.
MX2012007922A (es) Sellante de fibrina en polvo seco.
SG10201907152YA (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2010071894A3 (en) Tfpi inhibitors and methods of use
BR112015001955A2 (pt) variante de região fc específica de fcgamariib
SI2190473T1 (sl) Peptid z zmanjšano tvorbo dimerov
WO2010034718A8 (fr) Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire
MY195443A (en) Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
WO2014096440A3 (en) Albumin composition for preventing and/or reducing formation of peptide fibrils
WO2008135983A3 (en) Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders
EA201791898A1 (ru) Новые антитела, связывающиеся с tfpi, и содержащая их композиция
BR112013022217A8 (pt) composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
MX2019006444A (es) Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2021046389A9 (en) Compositions and methods for using silk-elastinlike protein-based polymers
EP4299585A3 (de) Zusammensetzungen und verfahren für antithrombotische und hämostatische therapien
MX2016004702A (es) Polipeptidos del factor vii de coagulacion.
WO2006135493A3 (en) A composition for wound healing and use thereof
BR112016005899A8 (pt) composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano, seus usos e método de purificação de uma proteína variante de fator xa.
WO2013142153A3 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
WO2009095646A3 (en) Peptides from factor viii
MX2015007625A (es) Composiciones sellantes.
MX2016013281A (es) Proteina del factor fviia con vida media extendida para la prevencion y tratamiento de sangrado y regimenes de dosificacion de la misma.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties